RESUMO
Druglike molecules are defined by Lipinski's rule of 5, to characterize fragment thresholds, they have been reduced from 5 to 3 (Astex's rule of 3). They are applied to assemble fragment libraries, and providers use them to select fragments for commercial offer. We question whether these rules are too stringent to compose fragment libraries with candidates exhibiting sufficient room for chemical subsequent growing and merging modifications as appropriate functional groups for chemical transformations are required. Usually these groups exhibit properties as hydrogen bond donors/acceptors and provide entry points for optimization chemistry. We therefore designed a fragment library (364 entries) without strictly applying the rule of 3. For initial screening for endothiapepsin binding, we performed a biochemical cleavage assay of a fluorogenic substrate at 1 mM. "Hits" were defined to inhibit the enzyme by at least 40%. Fifty-five hits were suggested and subsequently soaked into endothiapepsin crystals. Eleven crystal structures could be determined covering fragments with diverse binding modes: (i) direct binding to the catalytic dyad aspartates, (ii) water-mediated binding to the aspartates, (iii) no direct interaction with the dyad. They occupy different specificity pockets. Only 4 of the 11 fragments are consistent with the rule of 3. Restriction to this rule would have limited the fragment hits to a strongly reduced variety of chemotypes.
Assuntos
Ácido Aspártico Endopeptidases/química , Desenho de Fármacos , Modelos Moleculares , Relação Quantitativa Estrutura-Atividade , Bibliotecas de Moléculas Pequenas , Ácido Aspártico Endopeptidases/antagonistas & inibidores , Sítios de Ligação , Cristalografia por Raios X , Fluorescência , Ligação de Hidrogênio , Concentração de Íons de Hidrogênio , Estrutura Molecular , Ligação Proteica , Solubilidade , EstereoisomerismoRESUMO
Fragment-based drug discovery has gained a foothold in today's lead identification processes. We present the application of in silico fragment-based screening for the discovery of novel lead compounds for the metalloendoproteinase thermolysin. We have chosen thermolysin to validate our screening approach as it is a well-studied enzyme and serves as a model system for other proteases. A protein-targeted virtual library was designed and screening was carried out using the program AutoDock. Two fragment hits could be identified. For one of them, the crystal structure in complex with thermolysin is presented. This compound was selected for structure-based optimization of binding affinity and improvement of ligand efficiency, while concomitantly keeping the fragment-like properties of the initial hit. Redesigning the zinc coordination group revealed a novel class of fragments possessing K(i) values as low as 128 microM, thus they provide a good starting point for further hit evolution in a tailored lead design.
Assuntos
Inibidores de Proteases/química , Termolisina/antagonistas & inibidores , Aspirina/análogos & derivados , Aspirina/síntese química , Aspirina/farmacologia , Sítios de Ligação , Simulação por Computador , Cristalografia por Raios X , Bases de Dados de Proteínas , Desenho de Fármacos , Estrutura Terciária de Proteína , Software , Termolisina/metabolismoRESUMO
Plasmepsins (Plm) II (EC number: 3.4.23.39) and IV (EC number: 3.4.23.B14) are aspartic proteases present in the food vacuole of the malaria parasite Plasmodium falciparum and are involved in host hemoglobin degradation. Based on our established efficient synthetic sequence, a series of inhibitors for Plm II and IV has been synthesized bearing a 2,3,4,7-tetrahydro-1H-azepine scaffold as the core structural element. During the computational design cycle, thorough investigations were carried out in order to find a reasonable theoretical binding mode for Plm II and IV. The conformation of Plm II in the crystal structure (PDB code: 1LF2) provides a good starting geometry for our virtual screening approach. In contrast, the only available co-crystal structure for Plm IV of P. falciparum (PDB code: 1LS5) appears inappropriate for inhibitor design. Therefore, a homology model was constructed based on the Plm II 1LF2 structure. A combinatorial docking run using FlexX(c) suggested compounds which, after synthesis, turned out to exhibit affinities in the sub-micromolar range. The observed structure-activity relationships of the synthesized compounds confirm the assumed binding mode for Plm II and IV. The best-binding inhibitors designed for Plm II and IV are devoid of any inhibitory potency against human cathepsin D (EC number: 3.4.23.5).
Assuntos
Ácido Aspártico Endopeptidases/antagonistas & inibidores , Azepinas/síntese química , Azepinas/farmacologia , Desenho Assistido por Computador , Desenho de Fármacos , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , Animais , Ácido Aspártico Endopeptidases/química , Sítios de Ligação , Simulação por Computador , Cristalografia por Raios X , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/química , Ligantes , Modelos Químicos , Modelos Moleculares , Conformação Molecular , Plasmodium falciparum/enzimologia , Proteínas de Protozoários , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
At present nine FDA-approved HIV protease inhibitors have been launched to market, however rapid drug resistance arising under antiviral therapy calls upon novel concepts. Possible strategies are the development of ligands with less peptide-like character or the stabilization of a new and unexpected binding-competent conformation of the protein through a novel ligand-binding mode. Our rational design of pyrrolidinedimethylene diamines was inspired by the idea to incorporate key structural elements from classical peptidomimetics with a non-peptidic heterocyclic core comprising an endocyclic amino function to address the catalytic aspartic acid side chains of Asp 25 and 25'. The basic scaffolds were decorated by side chains already optimized for the recognition pockets of HIV protease or cathepsin D. A multistep synthesis has been established to produce the central heterocycle and to give flexible access to side chain decorations. Depending on the substitution pattern of the pyrrolidine moiety, single-digit micromolar inhibition of HIV-1 protease and cathepsin D has been achieved. Successful design is suggested in agreement with our modelling concepts. The subsequently determined crystal structure with HIV protease shows that the pyrrolidine moiety binds as expected to the pivotal position between both aspartic acid side chains. However, even though the inhibitors have been equipped symmetrically by polar acceptor groups to address the flap water molecule, it is repelled from the complex, and only one direct hydrogen bond is formed to the flap. A strong distortion of the flap region is detected, leading to a novel hydrogen bond which cross-links the flap loops. Furthermore, the inhibitor addresses only three of the four available recognition pockets. It achieves only an incomplete desolvation compared with the similarly decorated amprenavir. Taking these considerations into account it is surprising that the produced pyrrolidine derivatives achieve micromolar inhibition and it suggests extraordinary potency of the new compound class. Most likely, the protonated pyrrolidine moiety experiences strong enthalpic interactions with the enzyme through the formation of two salt bridges to the aspartic acid side chains. This might provide challenging opportunities to combat resistance of the rapidly mutating virus.